Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Infertility in Females01:28

Infertility in Females

Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of endometrial...
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
In Vitro Fertilization01:24

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do we trust scientific evidence? A multicentre retrospective analysis of first IVF/ICSI cycles before and after the OPTIMIST trial.

Human reproduction (Oxford, England)·2021
Same author

Impact of Italian legislation regulating assisted reproduction techniques on ICSI outcomes in severe male factor infertility: a multicentric survey.

Human reproduction (Oxford, England)·2007
Same author

Multiple tertiary interactions involving domain II of group II self-splicing introns.

Journal of molecular biology·1997
Same author

DNA methylation and gene expression: introduction and overview.

Mutation research·1997
Same author

DNA methylation, heterochromatin and epigenetic carcinogens.

Mutation research·1997
Same author

Carcinogenicity assessment of selected nickel compounds.

Toxicology and applied pharmacology·1997

Related Experiment Video

Updated: Jul 5, 2026

Fertility Preservation in Patients with Severe Ovarian Dysfunction
12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

Treating infertility in autoimmune patients.

M Costa1, D Colia

  • 1Department of Preconceptional and Prenatal Medicine, Galliera Hospital, Via Volta 6, 16145, Genoa, Italy. mauro.costa@galliera.it

Rheumatology (Oxford, England)
|June 25, 2008
PubMed
Summary

Systemic lupus erythematosus (SLE) and autoimmune diseases typically do not affect fertility. However, treatments like ovulation stimulation may pose risks for patients with SLE, requiring careful management and further research.

Related Experiment Videos

Last Updated: Jul 5, 2026

Fertility Preservation in Patients with Severe Ovarian Dysfunction
12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

Area of Science:

  • Reproductive immunology
  • Systemic autoimmune diseases
  • Infertility treatments

Background:

  • Fertility is generally preserved in patients with systemic lupus erythematosus (SLE) and other systemic autoimmune diseases.
  • Potential factors impairing fertility include anovulation during active disease, chronic renal failure, and certain medications (NSAIDs, corticosteroids, cyclophosphamide).
  • Antiphospholipid antibodies (aPLs) are associated with early pregnancy loss in SLE patients.

Purpose of the Study:

  • To review the current understanding of fertility in patients with SLE and systemic autoimmune diseases.
  • To assess the potential risks and outcomes associated with fertility treatments, including ovulation stimulation and assisted reproductive techniques (ARTs), in SLE patients.
  • To provide guidance on the management of SLE patients undergoing infertility treatments.

Main Methods:

  • Review of published literature on fertility, SLE, autoimmune diseases, and assisted reproductive techniques.
  • Analysis of reported risks of lupus exacerbation and thrombosis associated with controlled ovarian hyperstimulation and ARTs.
  • Evaluation of trends in pregnancy rates, live-birth rates, and maternal complications in SLE patients undergoing ARTs.

Main Results:

  • While fertility is often unaltered, it can be compromised by disease activity, complications, or specific treatments.
  • Evidence regarding the induction of SLE by ovulation stimulation is not conclusive, with some studies showing no increased frequency of fertility drug use in SLE patients.
  • Patients with SLE or primary antiphospholipid syndrome (APS) undergoing infertility treatment may face risks of disease flare or thrombosis.
  • A trend suggests a potentially worse prognosis for SLE patients undergoing ARTs regarding pregnancy and live-birth rates, and maternal complications.
  • Current data are insufficient, lacking prospective studies to definitively establish the safety and efficacy of ART in SLE patients.

Conclusions:

  • Careful management is crucial for SLE patients undergoing infertility treatments, particularly hormonal ovarian stimulation.
  • Recommended approach involves using low-dose gonadotropins in patients with quiescent disease for at least six months.
  • Further research, including prospective studies, is necessary to determine the safety and efficacy of ART in SLE patients.